On September 29, GENSCRIPT BIO fell 3.05% in regular trading, trading at HK$41.04/share, with turnover of approximately HK$114 million. The decline marks a second consecutive session of profit-taking, extending the pullback pattern seen on September 28 when shares dropped 3.12%.

The stock had surged over 20% within the month, propelled by the company's strategic partnership with Eli Lilly's AI-driven drug discovery platform Lilly TuneLab and broader AI pharmaceutical catalysts. Shares briefly topped HK$43 before retreating. Current prices have materially exceeded JPMorgan's previously stated target price of HK$41, intensifying near-term selling pressure from profit-takers.

Notably, JPMorgan had already executed a significant off-market disposal of approximately 33.75 million shares at an average price of HK$32.74, totaling roughly HK$1.105 billion, reducing its long position from 7.37% to 5.64%. This institutional-level partial realization signals a measured de-risking stance. On the fundamental side, Everbright Securities maintained a Buy rating, projecting triple-digit percentage growth in AI-driven protein orders for the second half and beyond, while the company recently completed a HK$2.33 billion share placement to expand its AIDD platform capacity.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)